I lost 6st on Mounjaro - this is what I've done to keep the weight off
A mum who shed an impressive 6st on Mounjaro has shared her secret to maintaining her weight loss successfully for eight months since stopping the injections.
Ellen Ogley, a 42 year old mother of three, tipped the scales at 16st 12lbs, wearing size 18 clothing at her heaviest point.
After losing three stone on what she described as an "unsustainable diet" and achieving a "quick fix" tummy tuck, Ellen was still not satisfied with her appearance.
Read more: Entire cabin crew suspended
It was the discovery of Mounjaro that truly made a difference, quelling her incessant craving for snacks and addressing her "food noise".
The Yorkshire-based nursery manager has since regulated her weight to an impressive 10st to 10st 3lbs, slipping into a size six attire, a change she has sustained for over half a year.
What's been crucial for her progress? She swapped frequent takeaways and heavy-drinking weekends for home-made 'fakeaways' and consistent weight training - a swap that has left her feeling "amazing".
Hailing from Ilkley, Ellen stated: "I wanted to make sure I wasn't reliant on Mounjaro."
Using the medication as a temporary aid, she reflected: "I used this as a tool."
Her commitment went beyond just dietary changes, as she emphasized: "I've done so much work on damage limitation."
With her transformation, Ellen aims to inspire others with the assurance that keeping the weight off is achievable, declaring: "I want to give others hope they can keep it off.
"I feel incredible," she enthused about her current state of well-being.
Ellen confesses that she resorted to "comfort eating" during a troubling time marked by illness, which escalated until she received a dual diagnosis of cervical and ovarian cancer.
In retrospect, she laid bare her unhealthy coping mechanisms: "I had blow outs and would have takeaways and binge drinking - it was a coping mechanism."
Admitting to her prior excessive indulgences, she shared: "I'd have two to three takeaways a week. My drinking was excessive."
She recalled the times when she and her husband would go through "My husband and I would have three bottles of wine between us - it helped numb everything."
Ellen underwent a necessary hysterectomy and was warned about elevated risks associated with her BMI, which peaked at 36.5. She made a promise to herself: "I said to myself 'if I come out the other side I will try and take control of my health'."
Post-recovery in September 2023, Ellen decided to lose weight but craved a "quick fix". In her own words: "I was looking for an easy way out."
She even consulted a surgeon hoping a cosmetic procedure would deliver fast results: "I went to see a surgeon for a tummy tuck."
Yet to qualify for both a tummy tuck and liposuction, she had a goal to shed three stone: "But I needed to lose three stone in order to have a tummy tuck and liposuction to get skinny."
Ellen embarked on intermittent fasting and stringent dieting, slimming down to 13st 10lbs, although she admits: "I was doing it in not a very healthy way."
The weight loss path wasn't without its challenges, as Ellen conceded: "I was almost starving myself."
Furthermore, she realized that such measures were far from a viable long-term plan: "It was not sustainable."
By February 2024, she completed a £10k tummy tuck, content with the outcomes but still desiring further weight decrease: "I only lost 4lbs more after the tummy tuck."
Her disappointment soon led to a preoccupation with her appearance: "I was devastated."
She struggled with her self-perception, particularly regarding her arms: "I became obsessed with my body - pulling at it."
Eventually, Ellen turned to weight loss medication, starting Mounjaro in May 2024 and combining it with cardiovascular training: "I thought it was going to be another diet trend but the food noises got switched off."
She noticed significant changes in her eating habits: "Before I would raid the cupboard when my husband took his daughter to gymnastics."
Inspiringly, once on the medication, she experienced a remarkable shift: "As soon as I went on I realised 'I've not touched the snack cupboard'."
This marked the beginning of improved lifestyle decisions: "I started making better lifestyle choices."
Ellen was on the jab for just 22 weeks, easing herself off gradually, but found herself fixated on getting as "skinny as possible".
She revealed: "I lost my focus."
She also shared her ordeal with online abuse: "I got trolled - they called me Skeletor, I was being told I looked like a 60-year-old."
It wasn't until her husband, Phil Ogley, 53, a surveyor, commented that she looked unwell that Ellen realised she needed to change, leading her to embrace weight training.
Now feeling "healthy and strong", Ellen has sustained her weight loss without relying on micro-dosing Mounjaro.
She expressed her successful strategy: "I've been learning how to fuel my body."
She's developed useful tricks: "I have hacks in place - if I'm craving sweets I have Greek yoghurt, berries and granola."
Ellen still indulges in the occasional takeaway, but practices portion control.
They've swapped out regular takeaways for homemade versions: "We make chicken kebabs as fakeaways instead of ordering them as takeaways."
The results astound her: "I have abs at 42 - it blows my mind."
Previously, her diet lacked structure with no breakfast, a jacket potato, cheese and beans for lunch, and a dinner of pasta bake followed by apple pie and custard. Snacking included a packet of biscuits and cookies.
Her current diet is more balanced: she starts her day with Greek yoghurt, berries, granola or overnight oats; lunch is a chicken salad; and dinner alternates between chicken with sweet potato fries and tortilla wrap pizzas.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Kennedy's new vaccine panel alarms pediatricians with inquiries into long-settled questions
ATLANTA (AP) — U.S. Health Secretary Robert F. Kennedy Jr.'s new vaccine advisers alarmed pediatricians Wednesday by announcing inquiries into some long-settled questions about children's shots. Opening the first meeting of Kennedy's handpicked seven-member panel, committee chairman Martin Kulldorff said he was appointing a work group to evaluate the 'cumulative effect' of the children's vaccine schedule — the list of immunizations given at different times throughout childhood. Also to be evaluated, he said, is how two other shots are administered — one that guards against liver-destroying hepatitis B and another that combines chickenpox protection with MMR, the measles, mumps and rubella vaccine. It was an early sign of how the Advisory Committee on Immunization Practices is being reshaped by Kennedy, a leading antivaccine activist before becoming the nation's top health official. He fired the entire 17-member panel this month and replaced it with a group that includes several anti-vaccine voices. 'Vaccines are not all good or bad,' Kulldorff said. 'We are learning more about vaccines over time' and must 'keep up to date.' His announcement reflected a common message of vaccine skeptics: that too many shots may overwhelm kids' immune systems or that the ingredients may build up to cause harm. Scientists say those claims have been repeatedly investigated with no signs of concern. Kids today are exposed to fewer antigens — immune-revving components — than their grandparents despite getting more doses, because of improved vaccine technology, said Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia. The American Academy of Pediatrics announced Wednesday that it would continue publishing its own vaccine schedule for children but now will do so independently of the ACIP, calling it 'no longer a credible process.' 'The narrative that current vaccine policies are flawed and need 'fixing' is a distortion," said the AAP's Dr. Sean O'Leary. "These policies have saved trillions of dollars and millions of lives." The ACIP, created more than 60 years ago, helps the Centers for Disease Control and Prevention determine who should be vaccinated against a long list of diseases, and when. Those recommendations have a big impact on whether insurance covers vaccinations and where they're available, such as at pharmacies. After Kennedy's abrupt dismissal of the existing expert panel, a number of the CDC's top vaccine scientists — including some who lead the reporting of data and the vetting of presentations at ACIP meetings — have resigned or been moved out of previous positions. And shortly before Wednesday's meeting, a Virginia-based obstetrician and gynecologist appointed to the committee stepped down. According to the Trump administration, he withdrew during a customary review of members' financial holdings. Scientists show data that COVID-19 vaccines protect pregnant women and kids First on the committee's agenda Wednesday were COVID-19 vaccinations. Kennedy already sidestepped the panel and announced the vaccine will no longer be recommended for healthy children or pregnant women. Yet CDC scientists told the panel that vaccination is 'the best protection' during pregnancy, and said most children hospitalized for COVID-19 over the past year were unvaccinated. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the CDC. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months who could have some protection if their mom got vaccinated during pregnancy, according to the CDC's presentation. The new advisers weren't asked to vote on Kennedy's recommendations, which raise uncertainty about how easily people will be able to access COVID-19 vaccinations this fall. After CDC staff outlined multiple overlapping systems that continue to track the vaccines' safety, several advisers questioned if the real-world data really is trustworthy. Committee will vote on RSV protections Next, the committee took up RSV, or respiratory syncytial virus, a common cause of cold-like symptoms that can be dangerous for infants. In 2023, U.S. health officials began recommending two new measures to protect infants — a lab-made antibody for newborns and a vaccine for pregnant women — that experts say likely drove an improvement in infant mortality. The committee will discuss another company's newly approved antibody shot and vote on updated recommendations. Flu shot recommendations to be debated At its June meetings, the committee usually refreshes guidance for Americans 6 months and older to get a flu shot, and helps green light the annual fall vaccination campaign. But a vote set for Thursday that also promises controversy. The panel is set to consider a preservative in a subset of flu shots that Kennedy and some antivaccine groups have falsely contended is tied to autism. In preparation, the CDC posted a new report confirming that research shows no link between the preservative, thimerosal, and autism or any other neurodevelopmental disorders. ___ Neergaard reported from Washington. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
2 hours ago
- Yahoo
Alberta reaches deal to donate imported children's pain medication to Ukraine
Alberta has reached a deal with a charitable organization to donate to Ukraine the province's surplus supply of children's pain medication it imported from Turkey two years ago in a deal that has become the subject of multiple investigations. Montreal-based Health Partners International of Canada (HPIC) told Postmedia on Tuesday that it had struck an agreement with Alberta Health Services (AHS) to accept as many as 1.4 million bottles of acetaminophen and ibuprofen to donate to the war-torn European country. The organization says once the donation is received, it will work with partner organizations and local government to identify where the supply is most needed. 'In essence we match what is needed to what we have available,' HIPC president Lois Brown stated in an email. 'Agreements with recipient partners include guarantees that all donated medicines will be used in accordance with applicable standard treatment guidelines.' HIPC partner organizations typically cover the costs of transportation for donated supplies. In April, Health Canada told Postmedia it had issued a 'no objection' letter in March to Alberta's request to donate the medication to Ukraine. The letter requires Alberta to ensure the drugs are only sold or donated abroad for humanitarian purposes, don't violate Ukrainian laws including import approvals, and that logistics and quality oversight are overseen by a compliant drug establishment licence holder. Turkish-base drug manufacturer Atabay had been seeking that licence though its status remains unclear. Postmedia's queries regarding the licence as well as details on quantity, timing, and cost were directed to the office of Hospital and Surgical Health Services Minister Matt Jones. AHS has previously said it was not part of the process of finalizing a donation agreement. The medication was imported in 2023 under exceptional circumstances amid a Canada-wide shortage, and is set to expire between January and March of next year, according to internal documents previously obtained by Postmedia. Less than a third of the planned shipment arrived, and much of the medication that did make it to Alberta went unused after the shortage ended. The imported acetaminophen proved unpopular due to its weaker dosage, and AHS told hospital staff to stop using the it six months after it arrived, in part because its thicker consistency posed a risk of clogging feeding tubes. The province's plan to recoup some costs by selling some of its supply to other provinces was abandoned amid unanimous lack of interest, and concern over its dosage, which is more common in Europe. Primary and Preventative Health Services Adriana LaGrange served as the health minister until mid-May when the province split the health portfolio into four new roles. In March, LaGrange described the medication as 'good quality drugs.' 'If we can't use them in Alberta, then we should be sending them to other countries,' she said. The $70-million deal in 2022 to bring in what was to be five million bottles of acetaminophen and ibuprofen has come under scrutiny following allegations of corruption by the former head of AHS regarding the procurement and contracting process. Those allegations have not been tested in court, and the government denies wrongdoing, but several inquiries into the deal are underway including the government's own investigation as well as others by the RCMP and Alberta's auditor general. As of last December, $49 million of the government's contract with Atabay remains unfulfilled, with the province seeking fulfill the balance by importing an intravenous adult pain medication. HIPC says it is the only Canadian charity licensed by Health Canada to handle donated medicines and has delivered more than $735 million in donated medicines and related supplies together with its partner organizations to over 130 countries since 1990. mblack@ Bookmark our website and support our journalism: Don't miss the news you need to know — add and to your bookmarks and sign up for our newsletters here. You can also support our journalism by becoming a digital subscriber. Subscribers gain unlimited access to The Edmonton Journal, Edmonton Sun, National Post and 13 other Canadian news sites. Support us by subscribing today: The Edmonton Journal | The Edmonton Sun.
Yahoo
3 hours ago
- Yahoo
Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends DOYLESTOWN, Pa., June 25, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and diabetic patients. ENT-03 was found to be safe and well tolerated at all doses evaluated as presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. The study results showed positive trends for both weight reduction and increased insulin sensitivity at higher tested doses. ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation. "Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies," said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma. "We are planning a Phase 1b study to evaluate dosing regimens, which we expect to initiate in the second half of 2025." The Phase 1a clinical trial was a single ascending dose study evaluating seven dose cohorts of ENT-03 in healthy obese subjects and obese subjects with type 2 diabetes (T2D). ENT-03 was administered subcutaneously (SQ) at six different doses. The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days. More information can be found on ENT-03 was very well tolerated and efficacy endpoints showed trends toward weight loss at higher doses for both obese and obese/T2D subjects, along with improvement in insulin sensitivity. About Metabolics PharmaMetabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity, type 2 diabetes, and MASH. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit View source version on Contacts Company contact: Richard Larson, M.D., Executive Officer, Chief Medical Officer, and Chairman of the BoardJohn DessoukiChief Financial
